logo
Plus   Neg
Share
Email

FirstCash Q1 Profit Tops Estimates - Quick Facts

FirstCash, Inc. (FCFS) reported first-quarter earnings per share of $0.96 compared to $0.97, prior year. On average, six analysts polled by Thomson Reuters expected the company to report profit per share of $0.89, for the quarter. Analysts' estimates typically exclude special items.

First-quarter adjusted revenue declined to $466.49 million from $467.60 million, last year. Analysts expected revenue of $465.28 million, for the quarter.

Due to the uncertainty around COVID-19 and the associated volatility of the Mexican peso, the company has decided to withdraw its previous earnings guidance.

Rick Wessel, CEO, said: "As of April 21, we have over $80 million of cash on hand and $200 million of available borrowing capacity under our unsecured lines of credit. Additional working capital also includes over $500 million in fully collateralized, short-term pawn loans and highly liquid, fast-turning inventories."

The Board of Directors declared a $0.27 per share second quarter cash dividend on common shares outstanding, which will be paid on May 29, 2020 to stockholders of record as of May 15, 2020. This represents an annual cash dividend of $1.08 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT